UPDATE 2-Biogen raises outlook as new MS drug again tops forecasts

April 23 (Reuters) - Biogen Idec Inc on Wednesday raised its full-year earnings and revenue forecasts as first-quarter sales of its new Tecfidera multiple sclerosis drug extended a run of eclipsing Wall Street sales expectations.